27
total announcements
SUNPHARMA.NS · 15 min delayed
Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited has published newspaper advertisements containing information about Postal Ballot/E-Voting.
Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited has announced a notice of postal ballot/e-voting for the reclassification of Mr. Sudhir Vrundavandas Valia, Mrs. Raksha Sudhir Valia, and Mrs. Krishna Vrundavandas Valia from the 'Promoter Group' to the 'Public' category. The proposal aims to reduce the promoter group holding from 54.48% to 52.68% and increase the public holding from 45.52% to 47.32%. The board has approved the proposal, and the necessary no-objection letters from the stock exchanges have been received.
Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited has informed the Exchange about the schedule of upcoming analyst/institutional investor meetings, which will be held on 01-Sept-26 at Ashwamedh – Elara India Dialogue 2026 in Mumbai. The company will not disclose any unpublished price sensitive information at these meetings.
Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited has received a favourable court decision in the Lipitor antitrust litigation, with the US Court of Appeals affirming the order granting summary judgment in favour of the company and its subsidiaries, and denying class certification to the plaintiffs.
Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited has received no-objection letters from the National Stock Exchange of India Limited and BSE Limited for the reclassification of certain promoters from the 'Promoter Group' category to the 'Public' category.
Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited has announced its Q1 FY27 earnings, with sales growing 10.1% to INR1,51,836 million, gross margin at 80.5%, and EBITDA margins at 28.9%. The company also mentioned a charge of INR1,617 million towards Organon's acquisition-related costs.
Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited has informed the Exchange about the schedule of upcoming analyst/institutional investor meetings.
Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited has informed the Exchange about an update on its credit rating, with CRISIL reaffirming the rating on the company's long-term bank facilities at 'CRISIL AAA/Stable' after removing the 'Rating Watch with Developing Implications' status.
Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited has informed the Exchange about publishing newspaper advertisements containing information about the Unaudited Financial Results for the quarter ended 30 June 2026.
Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited held its 34th Annual General Meeting (AGM) on July 31, 2026, and all resolutions were passed with the requisite majority. The voting results and scrutinizer report are available on the company's website.
Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited held its 34th Annual General Meeting on 31 July 2026, approving various resolutions, including the adoption of audited financial statements, appointment of directors, and declaration of a final dividend of Rs. 5.00 per equity share. The meeting was conducted through video conferencing, and remote e-voting was made available to members from 27 July 2026 to 30 July 2026.
Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited has made available the audio recording of its earnings call held on July 31, 2026, as per Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited concluded its Board Meeting held on 31 July 2026, which commenced at 10:50 A.M. and concluded at 3:40 P.M.
Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited has announced its unaudited standalone and consolidated financial results for Q1 of FY 2026-27, with revenue from operations at ₹57,411.3 crore and other income at ₹1,401.7 crore.
Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited has received approval from the Brazilian Health Regulatory Agency, ANVISA, to manufacture and market semaglutide in Brazil for the treatment of inadequately controlled type 2 diabetes mellitus.
Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited has published a newspaper advertisement and social media post regarding the opening of a Special Window for the transfer of physical shares, which were sold or purchased prior to April 1, 2019. The Special Window remains open until February 4, 2027, to facilitate the transfer of these shares.
Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited's partner Philogen has resubmitted the Marketing Authorization Application (MAA) for Nidlegy, a biopharmaceutical product for the neoadjuvant treatment of locally advanced, fully resectable melanoma, to the European Medicines Agency (EMA).
Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited has announced that the shareholders of Organon & Co. have approved the proposed acquisition of Organon by Sun Pharmaceutical Industries Limited, a significant milestone towards the completion of the transaction.
Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited has received approval from the South African Health Products Regulatory Authority (SAHPRA) to manufacture and market a generic version of semaglutide injection in South Africa for the treatment of adults with inadequately controlled type 2 diabetes mellitus.
Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited has informed the Exchange about the schedule of its meet and earnings call for the first quarter ended 30 June 2026, which will be held on 31 July 2026. The company will announce its results on the same day.